The partners have initiated a phase I trial to evaluate LuCaFab (ITM-31), a radiolabelled a-CA XII antibody Fab fragment, for the treatment of glioblastoma. The goal is to eradicate residual tumour cells following surgery to reduce the risk of relapse.

The financing round was supported by a selected network of investors from medical and financial sectors. It enables the start-up to advance its fully automated ‘lab-in-a-box’ system for the molecular diagnosis of skin diseases to the market.

Supported by Ascenion, Matthias Bruhn and his team at TWINCORE - Centre for Experimental and Clinicial Infection Research have attracted EUR 97,000 to explore the commercial feasibility of their MEMUMAB project. The goal is to provide therapeutic antibodies against infectious diseases such as COVID-19.

The German Federal Ministry of Education and Research (BMBF) is providing EUR 6.5 million in funding for 10 selected research projects targeting long-term symptoms of COVID-19. Ascenion’s partner institutes are making significant contributions to three of these projects.

The method, SARSeq (Saliva Analysis by RNA sequencing), enables highly sensitive, massively-parallel and cost-effective testing for SARS-CoV-2. Ascenion has supported its patent protection and licencing for commercial use in China.

The start-up has also been certified as a medical device manufacturer in the EU. Its x-c-bleeding product uses AI-based software to predict the risk of post-operative bleeding in patients in intensive care units.

The start-up has dosed the first participant in a Phase I study with its lead candidate HRX-0215. The small molecule holds strong potential to restore the liver’s natural capacity to regenerate itself, both in acute and chronic liver disease.

Scientists from the Helmholtz Institute for RNA-based Infection Research (HIRI) and the Julius Maximilian University (JMU) in Würzburg have paved the way for a new diagnostic platform that enables the detection of multiple markers in one single test.

Ascenion’s portfolio company HepaRegeniX achieves an important preclinical milestone indicating beneficial therapeutic effects of its lead candidate in certain liver carcinomas.

Ascenion’s portfolio company iThera gained regulatory approval for a pivotal trial evaluating its MSOT imaging technology for the assessment of colon inflammation. If successful, it could provide a superior, non-invasive alternative to colonoscopy.

HepaRegeniX has demonstrated proof-of-efficacy in acute liver disease in preclinical studies performed in collaboration with the University Hospital of Tübingen (Germany) and the Mayo Clinic (Rochester, MN, USA).

Newly founded dentalXrai provides a unique, AI-based platform to improve and speed up the analysis of dental X-ray images. Ascenion, technology transfer partner of the Charité – Universitätsmedizin Berlin, holds equity in the start-up.

Cardior Pharmaceuticals GmbH has published results of preclinical in vivo studies in Nature Communications showing that its lead compound, CDR132L, can significantly improve the functioning of pathologically altered hearts.

A research team at the German Center for Neurodegenerative Diseases (DZNE) has received the ‘Hugo Junkers Award for Research and Innovation from Saxony-Anhalt 2019’.

Ascenion’s portfolio company Berlin Cures has initiated a Phase IIa clinical study with its lead compound BC 007. The two-armed, randomized,…

Ascenion’s portfolio company OMEICOS dosed a first patient in a Phase II clinical trial for its lead program OMT-28. The placebo-controlled,…

Gramibactin is an iron-binding molecule of the siderophore family. It occurs naturally in certain plant-associated bacteria where it helps secure the…

Ascenion GmbH, the technology transfer partner of the Helmholtz Centre for Infection Research (HZI), has supported the negotiations for a…

Ascenion Negotiated Additional Licence Agreement between Helmholtz Zentrum München and Medigene

9 January 2019, Munich – The Helmholtz Zentrum…

Following the successful completion of a Phase I trial with its cardioprotective lead candidate OMT-28, OMEICOS has now closed a Series C financing…

iThera Medical, a spin-off from the Helmholtz Zentrum München, has closed series C financing with new investors FLUXUNIT, the corporate venture…

Amgen announced that the Japanese Ministry of Health, Labour and Welfare has granted marketing approval for BLINCYTO® (blinatumomab) for the treatment…

Shire’s VEYVONDI received EU market authorization for the treatment of bleeding events and the prevention or treatment of surgical bleeding in…

Ascenion has negotiated a licence agreement between Medical School Hannover (MHH) and its spin-off Cardior Pharmaceuticals providing the company with…

Ascenion, the knowledge and technology transfer partner of the Helmholtz-Zentrum Dresden-Rossendorf (HZDR), has negotiated an agreement with Roche…

The European Commission has granted approval for Amgen’s BLINCYTO® (blinatumomab) for the treatment of pediatric patients with certain forms of B cell…

Drug developer Berlin Cures announced the successful completion of its Phase 1 study of its lead candidate BC 007 for the treatment of cardiomyopathy.…

Ascenion’s portfolio company OMEICOS reported positive Phase I data for its lead candidate OMT-28, a small molecule with strong anti-arrhythmic and…

Phase I study initiated with candidate against multidrug-resistant germs 

6 June 2018, Munich – The Leibniz Institute for Natural Product Research…

The U.S. Food and Drug Administration (FDA) has extended the scope of Shire’s VONVENDI to include perioperative management of bleeding in adults with…

Berlin Cures, one of Ascenion’s portfolio companies, has announced positive Phase I results for its lead candidate BC007 for the treatment of heart…

Making cancer surgery more precise

23 October 2017, Munich – SurgVision BV, a spin-off from the Helmholtz Zentrum München, has been acquired by…

OMEICOS Therapeutics, a spin-off from the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), announced the second closing…

A consortium of nine partners from five European countries, led by the Helmholtz Zentrum München, will work together with a transdisciplinary approach…

OMEICOS Therapeutics, a spin-off from the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), announced the first closing…

Heidelberg Pharma, a subsidiary of Wilex AG, and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC) have signed a…

LentiBOOST^TM, an innovative gene therapy adjuvant, has got the green light from the FDA for use in a Phase III clinical trial. The technology, which…

Tubingen (Germany), January 05, 2017 – HepaRegeniX GmbH, a new Biotech company developing innovative treatments for liver diseases, announced today…

amcure, a company that received support from Ascenion’s Spinnovator coaching program from the beginning, reports a significant milestone: At the end…

Berlin Cures, one of Ascenion’s investment portfolio companies, has announced the start of a clinical trial with its lead candidate BC007. The Phase I…

19 September 2016, Munich – Ascenion GmbH, the technology transfer partner of the Max Delbrück Center for Molecular Medicine in the Helmholtz…

A ground-breaking approach to the therapy of HIV infection has been published in the current issue of Nature Biotechnology: a designer recombinase…

21 December 2015, Berlin and Munich - ‘VONVENDI [von Willebrand factor (Recombinant)]’, the new drug from Baxalta Incorporated, a global…

The first clinical trial of MSOT, iThera’s innovative imaging technique, has made it onto the cover of the prestigious journal Science Translational…

The US biotech company Amgen announced at the end of November that its cancer therapy BLINCYTO^® has been approved by the European Commission for the…

amcure, a spin-off from the Karlsruhe Institute of Technology (KIT), has received a further EUR 1.9 million funding from the German Federal Ministry…

Recent Publication in Key Scientific Journal Supports amcure’s Therapeutic Approach in Cancer

Ascenion’s portfolio company OMEICOS, a spin-off from the Max Delbrück Center for Molecular Medicine (MDC) in Berlin, has received further funding of…

BigChem GmbH was founded this October to commercialize validated IT products and services developed at the Helmholtz Zentrum München. The research was…

As recently announced by Ascenion’s portfolio company Protectimmun, the three parties have agreed that Janssen will financially support preclinical…

The negotiation of a licensing and cooperation agreement between Formula Pharmaceuticals and the Helmholtz Association’s Max Delbrück Center for…